« Zurück
Startseite /
Silmitasertib (sodium salt)

Silmitasertib (sodium salt)

ArtNr	HY-50855B-500mg
Hersteller	MedChem Express
CAS-Nr.	1309357-15-0
Menge	500 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 g 500 mg 50 mg 5 mg
Kategorie	Oncology Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Breast Cancer
Typ	Inhibitors
Specific against	other
Purity	99.92
Citations	[1]Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98.\|[2]Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40.\|[3]Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.\|[4]Kendall JJ, et al. CK2 blockade causes MPNST cell apoptosis and promotes degradation of β-catenin. Oncotarget. 2016 Aug 16;7(33):53191-53203. Cancer Cell Int. 2024 Dec 26;24(1):432.\|Int J Mol Sci. 2021 Jan 15;22(2):E819.\|Metabolism. 2024 Nov 7:162:156060.\|Oncotarget. 2016 Aug 16;7(33):53191-53203.\|Autophagy. 2024 Aug 22.\|Biochem Biophys Res Commun. 2020 Oct 20;531(3):409-415.\|Biomed Pharmacother. 2024 Jul 29:178:117191.\|bioRxiv. 2023 Oct 23.\|bioRxiv. 2024 Jul 25:2024.07.25.605073.\|bioRxiv. 2024 Nov 6:2024.11.04.621884.\|bioRxiv. 2025 February 07.\|Cancer Biol Ther. 2025 Dec;26(1):2457777.\|Cancers (Basel). 2021, 13(5), 1127.\|Cell Death Dis. 2024 Mar 16.\|Cell Death Discov. 2024 Apr 22;10(1):185.\|Cell Mol Biol Lett. 2023 Oct 24;28(1):85.\|Cell Rep Methods. 2023 Oct 23;3(10):100599.\|Cell Rep. 2023 Apr 3;42(4):112339.\|Cell Stem Cell. 2023 Apr 6;30(4):450-459.e9.\|Cells. 2021 Jan 18;10(1):E181.\|Drug Res (Stuttg). 2024 Mar 20.\|Electronic Theses and Dissertations. 2023 Jul.\|EMBO Mol Med. 2020 Aug 7;12(8):e11987.\|Heliyon. 2024 Aug 18;10(16):e36205.\|Immunol Cell Biol. 2024 Nov 28.\|Int J Biol Macromol. 2024 Dec 2:138305.\|Int J Mol Sci. 2020 Mar 3;21(5):1718. \|Invest Ophthalmol Vis Sci. 2022 Dec 1;63(13):14.\|iScience. 2025 Jan 7.\|iScience. 2025 Jan 7;28(2):111765.\|J Biol Chem. 2024 Sep 30:107848.\|J Immunol. 2023 Mar 27;ji2200598.\|J Med Chem. 2023 Mar 6.\|J Med Chem. 2023 Mar 8.\|Nat Cell Biol. 2021 Mar;23(3):257-267.\|Nat Commun. 2023 Feb 9;14(1):731.\|Nat Commun. 2024 Oct 16;15(1):8912.\|Oncogene. 2017 Aug 24;36(34):4943-4950.\|Oncogene. 2022 Jan;41(4):571-585.\|Oncol Rep. 2017 Feb;37(2):1141-1147. \|Patent. US20180263995A1.\|Research Square Preprint. 2023 May 26.\|Research Square Preprint. 2023 Oct 27.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Science. 2017 Dec 1;358(6367):eaan4368.\|Signal Transduct Target Ther. 2023 May 10;8(1):183.\|University of California. 2023 Feb.\|University of Concepcion. 2023.
Smiles	O=C(C1=CC=C2C3=C(C(NC4=CC=CC(Cl)=C4)=NC2=C1)C=CN=C3)O[Na]
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CX-4945 (sodium salt)
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Autophagy; Casein Kinase
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	371.75
Product Description	Silmitasertib sodium salt is an orally bioavailable, highly selective and potent CK2 inhibitor, with IC50 values of 1 nM against CK2α and CK2α'.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 87.5 mg/mL (ultrasonic)\|H2O: 16.67 mg/mL (ultrasonic)
Manufacturer - Pathway	Autophagy; Cell Cycle/DNA Damage; Stem Cell/Wnt
Isoform	CK2
Clinical information	Phase 2

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-50855B-500mg-safety-datasheet.pdf